A Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of ALX 0171 Versus Placebo, in Addition to Standard of Care, in Adults Who Have Undergone Hematopoietic Stem Cell Transplantation and Present With a Respiratory Syncytial Virus Respiratory Tract Infection
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2019
At a glance
- Drugs ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Ablynx
- 16 Feb 2019 This trial has been discontinued in Germany and Italy.
- 14 Feb 2019 This trial has been discontinued in Spain.
- 13 Feb 2019 The trial has been completed in Belgium .